BioArctic AB (publ) (BRCTF)
| Market Cap | 3.01B +6.4% |
| Revenue (ttm) | 103.43M -46.1% |
| Net Income | 10.89M -90.1% |
| EPS | 0.12 -90.1% |
| Shares Out | n/a |
| PE Ratio | 276.28 |
| Forward PE | 38.44 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 34.05 |
| Previous Close | 34.05 |
| Day's Range | 34.05 - 34.05 |
| 52-Week Range | 27.82 - 40.00 |
| Beta | -0.68 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 26, 2026 |
About BioArctic AB
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and ALS. In addition, it offers lecanemab for intravenous treatment. Further, it is developing lecanemab for subcutaneous treatment; lecanemab, which is in Phase 3 clinical trials for presymptomatic ... [Read more]
News
Number of shares and votes in BioArctic AB (publ) as of August 31, 2026
STOCKHOLM, Aug. 31, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 20,200 Class B shares during August for delivery of shares to participan...
BioArctic AB Earnings Call Transcript: Q2 2026
Leqembi achieved FDA approval and U.S. launch for its subcutaneous formulation, driving global sales growth and expanding patient access. Strategic partnerships with Eli Lilly and Mesenkia validate and broaden the BrainTransporter platform, while strong financials and robust recurring revenues support continued R&D investment.
BioArctic AB Quarterly report: Q2 2026
BioArctic AB has published its Q2 2026 quarterly earnings report on August 26, 2026.
BioArctic AB Slides: Q2 2026
BioArctic AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 26, 2026.
BioArctic: Interim Report for the period April - June 2026
New approvals for Leqembi ® and additional strategic partnerships STOCKHOLM, Aug. 26, 2026 /PRNewswire/ -- Events during the second quarter 2026 Eisai provided a sales forecast for Leqembi for the co...
Leqembi Iqlik® for initiation treatment launched in the US
STOCKHOLM, Aug. 24, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced that lecanemab-irmb subcutaneous injection (US brand name: Leqembi Iqlik®), whic...
BioArctic And Mesenkia Launch Collaboration On Antibody-Based Glioblastoma Therapy
(RTTNews) - BioArctic AB (BIOA B) and Mesenkia Therapeutics announced a research collaboration to develop a novel antibody-based approach for glioblastoma, one of the most aggressive and treatment-res...
BioArctic and Mesenkia enter oncology research collaboration
STOCKHOLM, August 19, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) and Mesenkia Therapeutics announced today that the companies have signed a research collaboration agreement to...
Invitation to presentation of BioArctic's second quarter report for April - June 2026 on August 26 at 9:30 a.m. CEST
STOCKHOLM, August 19, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's second quarter report for April - June 2026 on Wednesday, August 26, 2026, at 8:00 ...
Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026
STOCKHOLM, July 29, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conju...
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
STOCKHOLM, July 14, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Stud...
FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
STOCKHOLM, July 13, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the US Food and Drug Administration (FDA) has approved a supplemental Biolo...
New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease
STOCKHOLM, July 13, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data at the 2026 Alzheimer's Association International Conference (AAIC), he...
New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026
STOCKHOLM, June 30, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at the Alzheimer's Ass...
BioArctic AB Press release: Collaboration
BioArctic AB issued a press release on June 23, 2026, disclosing material business information to investors.
BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic's BrainTransporter™ technology
STOCKHOLM, June 22, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the company has entered into a research and collaboration agreement with Eli Lilly and Comp...
Number of shares and votes in BioArctic AB (publ) as of May 29, 2026
STOCKHOLM, May 30, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 5,000 Class B shares during May for delivery of shares to participants in...
Bulletin from the Annual General Meeting in BioArctic AB (publ)
STOCKHOLM, May 28, 2026 /PRNewswire/ -- Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm, whereby the following resolutions were made. Adoption of the...
BioArctic's partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day
STOCKHOLM, May 25, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation [1] of potential future sales for Leqembi. ...
BioArctic Interim Report for the period January - March 2026
STOCKHOLM, May 20, 2026 /PRNewswire/ -- Strong financial performance with commercial milestone reached Events during the first quarter 2026 Leqembi® Iqlik™ (subcutaneous formulation) was granted Prior...
BioArctic AB Earnings Call Transcript: Q1 2026
Q1 2026 saw robust royalty growth and strong cash reserves, driven by Leqembi's global expansion and pipeline progress. Regulatory and reimbursement hurdles persist in Europe, but U.S. and Asian markets are fueling blockbuster momentum.
BioArctic AB Quarterly report: Q1 2026
BioArctic AB has published its Q1 2026 quarterly earnings report on May 20, 2026.
BioArctic AB Slides: Q1 2026
BioArctic AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 20, 2026.
Invitation to presentation of BioArctic's first quarter report for January - March 2026 on May 20 at 9:30 a.m. CET
STOCKHOLM, May 13, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's first quarter report for January - March 2026 on Wednesday, May 20, 2026, at 8:00 a.m....
Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S.
STOCKHOLM, May 8, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by...